Leukemia Research
Volume 25, Issue 8 , Pages 665-671 , August 2001

Treatment of patients with myelodysplastic syndrome with amifostine

  • A Galanopoulos

      Affiliations

    • Department of Clinical Hematology, ‘G. Gennimatas’ General Hospital, Athens, Greece
    • Corresponding Author InformationCorresponding author. Present address: Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N., D1-100, Seattle, WA 98109-1024, USA. Fax: +1-206-667-6124
    • ,
  • E Kritikou-Griva

      Affiliations

    • Department of Laboratory Hematology, ‘G. Gennimatas’ General Hospital, Athens, Greece
    • ,
  • J Gligori

      Affiliations

    • Department of Laboratory Hematology, ‘G. Gennimatas’ General Hospital, Athens, Greece
    • ,
  • E Michalis

      Affiliations

    • Department of Clinical Hematology, ‘G. Gennimatas’ General Hospital, Athens, Greece
    • ,
  • V Grigoraki

      Affiliations

    • Department of Clinical Hematology, ‘G. Gennimatas’ General Hospital, Athens, Greece
    • ,
  • T Marinakis

      Affiliations

    • Department of Clinical Hematology, ‘G. Gennimatas’ General Hospital, Athens, Greece
    • ,
  • J Kakkas

      Affiliations

    • Department of Clinical Hematology, ‘G. Gennimatas’ General Hospital, Athens, Greece
    • ,
  • A Tasiopoulou

      Affiliations

    • Department of Laboratory Hematology, ‘G. Gennimatas’ General Hospital, Athens, Greece
    • ,
  • N.I Anagnostopoulos

      Affiliations

    • Department of Clinical Hematology, ‘G. Gennimatas’ General Hospital, Athens, Greece

Received 1 September 2000 ,Accepted 9 December 2000.

References 

  1. Dansey R. Myelodysplasia. Curr. Opin. Oncol. 2000;12:13
  2. Gordon MS. Advances in supportive care of myelodysplastic syndromes. Semin. Hematol. 1999;36(Suppl. 6):21
  3. Deeg HJ, Shulman HM, Anderson JE, Bryant EM, Gooley TA, Slattery JT, et al. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55–66 years of age. Blood. 2000;95:1188
  4. List AF, Heaton R, Glinsmann-Gibson B, Capizzi R. Amifostine stimulates formation of multipotent progenitors and generates macroscopic colonies in normal and myelodysplastic bone marrow. Proc. ASCO. 1996;15:449
  5. List AF, Brasfield F, Heaton R, Gibson BG, Crook L, Taetle R, et al. Stimulation of hematopoiesis by amifostine in patients with myelodyslastic syndrome. Blood. 1997;90:3364
  6. List AF, Heaton R, Gibson BG, Capizzi RL. Amifostine stimulates formation of multipotent and erythroid bone marrow progenitors. Leukemia. 1998;12:1596
  7. Capizzi RL, Scheffler BJ, Schein PS. Amifostine-mediated protection of normal bone marrow from cytotoxic chemotherapy. Cancer. 1993;72(Supp.):3495
  8. Poloni AP, Leoni P, Curzi L, Cantori I, Mancini S, Montanari M, et al. Ex vivo pharmacological purging of leukapheresis collections with nitrogen mustard: amifostine pretreatment improves both early and late peripheral blood progenitor cell recovery. Exp. Hematol. 1999;27:1548
  9. Santini V, Giles JF. The potential of amifostine: from cytoprotectant to therapeutic agent. Haematologica. 1999;84:1035
  10. Kemp G, Rose P, Lurain J, et al.  Amifostine pretreatment for protection against cyclophosphamide-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J. Clin. Oncol. 1966;14:2101
  11. Romano MF, Lamberti A, Bisogni R, Garbi C, Pagnano AM, Auletta P, et al. Amifostine inhibits hematopoietic progenitor cell apoptosis by activating NF-κB/Rel transcription factors. Blood. 1999;94:4060
  12. Moroni M, Porta C, Invernizzi R, Inzoli A, Pallavicini FB, Pallavicini EB. ‘Tunel’ evidence of reduced bone marrow cells apoptosis in a refractory anaemia patient treated with amifostine. Br. J. Haematol. 1999;104:424
  13. Fenaux P. Myelodysplastic syndromes. In:  Degos L,  Linch DC,  Lowemberg B editor. Textbook of malignant haematology. London: Martin Dunitz; 1999;p. 787
  14. Grossi A, Fabbri A, Santini V, Leoni F, Nozzoli C, Longo G, et al. Amifostine in the treatment of low-risk myelodysplastic syndromes. Haematologica. 2000;85:367
  15. Orkin SH, Harosi RI, Leder P. Differentiation in erythroleukemic cells and their somatic hybrids. Proc. Natl. Acad. Sci. USA. 1975;72:98
  16. Raza A, Andric T, Qawi H, et al.  Combination of pentoxifylline, ciprofloxacin, dexamethasone with amifostine improves ineffective hematopoiesis in patients with myelodysplastic syndromes. Blood. 1997;80(Suppl. 1):367a
  17. de Castro CM, Gockerman JP, Moore JO, et al.  Preliminary results of a phase II study of amifostine for patients with myelodysplastic syndrome. Blood. 1997;80(Suppl. 1):4034a
  18. Bowen DT, Denzlinger C, Brugger W, Culligan D, Gelly K, Adlakha S, et al. Poor response rate to a continuous schedule of amifostine therapy for ‘low/intermediate risk’ myelodysplastic patients. Br. J. Haematol. 1998;103:785
  19. List AF, Heaton R, Glinsmann-Gibson B, Capizzi R. Amifostine stimulates formation of multipotent progenitors and generates macroscopic colonies in normal and myelodysplastic bone marrow. Proc. ASCO. 1996;15:449
  20. Dorr RT, Holmes B. Dosing considerations with amifostine: a review of the literature and clinical experience. Semin. Oncol. 1999;26(Suppl. 7):108
  21. Santini V, Giles F. The potential of amifostine: from cytoprotectant to therapeutic agent. Haematologica. 1999;84:1035
  22. Shaw L, Brown W, Schein P, Stogniew M. A phase I study comparing the relative bioavailability of intravenous (IV) and subcutaneous (SC) administration of amifostine (Ethyol). Proc. ASCO. 1997;16:883
  23. Brasfield FM, Heaton R, Glinsmann-Gibson B, Obregon Y, Talley M, Taetle R, et al. Phase I/II trial of subcutaneous amifostine in patients with myelodysplastic syndrome(MDS). Proc. ASCO. 1998;17:13
  24. Kempin S, Sirott M, Cecchi G, Irwin D, Gee T, Stepan D, et al. Phase II study of amifosine for the treatment of the myelodysplastic syndrome (MDS). Proc. ASCO. 1998;17:108
  25. Hofmann WK, Seipelt G, Ottmann OG, Kalina U, Koschmieder S, Brucher J, et al. Effect of treatment with amifostine used as a single agent in patients with refractory anemia on clinical outcome and serum tumor necrosis factor alpha levels. Ann. Hematol. 2000;79:255
  26. List AF, Holmes H, Greenberg PL, Bennett JM, Oster W. Phase II study of amifostine in patients with myelodysplastic syndromes (MDS). Blood. 1999;94(Supp. 1):305a
  27. Tefferi A, Elliott MA, Hook CC, Dispenzieri A, Hanson CA, Letendre L. Amifostine alone and in combination with erythropoietin for the treatment of myelodysplastic syndrome. Blood. 1999;94(Suppl. 1):305a
  28. Kim PS, Rosmarin AG, Mega A, Calabresi P. The cytoprotectant amifostine (AMF) potentiates 5-azacytidine (AZA-C) cytotoxicity in the myelodysplastic syndrome. Blood. 1999;94(Suppl. 1):305a
  29. Raza A, Qawi H, Lisak L, Andric T, Dar S, Andrews C, et al. Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone. Blood. 2000;95:1580
  30. List AF. Use of amifostine in hematologic malignancies, myelodysplastic syndrome, and acute leukemia. Semin. Oncol. 1999;26(Suppl. 7):61

PII: S0145-2126(01)00004-2

Leukemia Research
Volume 25, Issue 8 , Pages 665-671 , August 2001

Article Tools

* Image Usage & Resolution